These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

835 related items for PubMed ID: 28304292

  • 1. Amyloid-β Deposition and Long-Term Progression in Mild Cognitive Impairment due to Alzheimer's Disease Defined with Amyloid PET Imaging.
    Hatashita S, Wakebe D.
    J Alzheimers Dis; 2017; 57(3):765-773. PubMed ID: 28304292
    [Abstract] [Full Text] [Related]

  • 2. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction.
    Hatashita S, Yamasaki H.
    PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136
    [Abstract] [Full Text] [Related]

  • 3. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L, Chiotis K, Alongi P, Almkvist O, Wall A, Cerami C, Bettinardi V, Gianolli L, Nordberg A, Perani D.
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [Abstract] [Full Text] [Related]

  • 4. Evaluation of PiB visual interpretation with CSF Aβ and longitudinal SUVR in J-ADNI study.
    Okada Y, Kato T, Iwata K, Kimura Y, Nakamura A, Hattori H, Toyama H, Ishii K, Ishii K, Senda M, Ito K, Iwatsubo T, Japanese Alzheimer’s Disease Neuroimaging Initiative.
    Ann Nucl Med; 2020 Feb; 34(2):108-118. PubMed ID: 31749127
    [Abstract] [Full Text] [Related]

  • 5. Longitudinal Assessment of Amyloid-β Deposition by [18F]-Flutemetamol PET Imaging Compared With [11C]-PIB Across the Spectrum of Alzheimer's Disease.
    Hatashita S, Wakebe D, Kikuchi Y, Ichijo A.
    Front Aging Neurosci; 2019 Feb; 11():251. PubMed ID: 31572167
    [Abstract] [Full Text] [Related]

  • 6. Long-Term Interrelationship between Brain Metabolism and Amyloid Deposition in Mild Cognitive Impairment.
    Kemppainen N, Joutsa J, Johansson J, Scheinin NM, Någren K, Rokka J, Parkkola R, Rinne JO.
    J Alzheimers Dis; 2015 Feb; 48(1):123-33. PubMed ID: 26401934
    [Abstract] [Full Text] [Related]

  • 7. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH, Kim BI, Park SY, Ko IO, Lee KC, Kim KM, Kim YK, Lee JY, Bu SH, Kim JH, Chi DY, Ha JH, Lim SM.
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [Abstract] [Full Text] [Related]

  • 8. Urine AD7c-NTP Predicts Amyloid Deposition and Symptom of Agitation in Patients with Alzheimer's Disease and Mild Cognitive Impairment.
    Zhang N, Zhang L, Li Y, Gordon ML, Cai L, Wang Y, Xing M, Cheng Y.
    J Alzheimers Dis; 2017 Mar; 60(1):87-95. PubMed ID: 28777752
    [Abstract] [Full Text] [Related]

  • 9. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N, Chételat G, Grassiot B, Bourgeat P, Jones G, Ellis KA, Ames D, Martins RN, Eustache F, Salvado O, Masters CL, Rowe CC, Villemagne VL, AIBL Research Group.
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Imaging characteristic of dual-phase (18)F-florbetapir (AV-45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition in Alzheimer's disease and mild cognitive impairment.
    Lin KJ, Hsiao IT, Hsu JL, Huang CC, Huang KL, Hsieh CJ, Wey SP, Yen TC.
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(7):1304-14. PubMed ID: 27003417
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of imaging biomarkers for Alzheimer's disease: amyloid imaging with [18F]florbetapir positron emission tomography and magnetic resonance imaging voxel-based analysis for entorhinal cortex atrophy.
    Tateno A, Sakayori T, Kawashima Y, Higuchi M, Suhara T, Mizumura S, Mintun MA, Skovronsky DM, Honjo K, Ishihara K, Kumita S, Suzuki H, Okubo Y.
    Int J Geriatr Psychiatry; 2015 May; 30(5):505-13. PubMed ID: 25043833
    [Abstract] [Full Text] [Related]

  • 18. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias.
    Bao YW, Chau ACM, Chiu PK, Shea YF, Kwan JSK, Chan FHW, Mak HK.
    J Alzheimers Dis; 2021 May; 79(2):819-832. PubMed ID: 33361593
    [Abstract] [Full Text] [Related]

  • 19. Five-year follow-up of 11C-PIB uptake in Alzheimer's disease and MCI.
    Kemppainen NM, Scheinin NM, Koivunen J, Johansson J, Toivonen JT, Någren K, Rokka J, Karrasch M, Parkkola R, Rinne JO.
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):283-9. PubMed ID: 24072346
    [Abstract] [Full Text] [Related]

  • 20. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
    Espinosa A, Alegret M, Pesini P, Valero S, Lafuente A, Buendía M, San José I, Ibarria M, Tejero MA, Giménez J, Ruiz S, Hernández I, Pujadas F, Martínez-Lage P, Munuera J, Arbizu J, Tárraga L, Hendrix SB, Ruiz A, Becker JT, Landau SM, Sotolongo-Grau O, Sarasa M, Boada M, AB255 Study Group, Alzheimer’s Disease Neuroimaging Initiative.
    J Alzheimers Dis; 2017 Feb; 57(2):447-459. PubMed ID: 28269787
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.